Sarepta

Rare Disease Therapeutics · Cell & Gene Therapy
Has an LEISponsors visas
8Open roles7 posted in 30 days+2 this week
$201kMedian advertised pay$145k – $217k+6% vs market
26 daysTime to fillmedian of 11 closed rolesmarket: 31 days
$2.2BRevenue, 2025net income −$713.4M+15.6% a year
Lately:+2 roles posted this week8 news stories in 90 daysFollow changes →

Facts

as of Nov 18, 2026

We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.

It is hiring: 8 open roles, 7 of them posted in the last 30 days.

Legal name
Sarepta Therapeutics, Inc.
Headquarters
Cambridge, United States
Employees
501-1000estimated range
Revenue
$2.2B2025 · SEC
Open roles
8 in 11 citiesAlion job postings
Register numbers
EIN 930797222

As of Nov 18, 2026, Alion lists 8 open roles at Sarepta. Sarepta is headquartered in Cambridge, United States. The median pay stated in its open roles is $201k, across 8 postings that state pay.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Legal entity active
Sarepta Therapeutics, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Hiring at full speed: most open roles are fresh.

Biotech is the largest family, 32 of open roles.

7Posted in 30 days78% of open roles are fresh
0%Remote roles0 of 9
11Hiring offices
Can they hire you from United States?by your location
Likely
20 open roles are in your country: you apply locally, no move needed.
United States20On site
Remote, from elsewhere0Rare
No posting offers visa sponsorship. Remote roles: 0.
Time to fillmedian days to close a role
Sarepta26 days
Market, same roles31 days
Alion signals0-100
Demand9
Pay35
Your chance39
How badly they need people, whether they pay, how realistic getting in is.
Open roles over time−100%
Sep 28This week
Open roles a week: 6 then, 0 now
Where the openings areshare of open roles · trend
Biotech32▲
Marketing11▲
Sales11▼
Operations11▲
QA5▼
Leadership5▼
Newest roles
Manager, Global Regulatory Strategy
$116k – $145k per year · Hybrid · Full-Time · Cambridge
Senior Manager, CMC Regulatory
Hybrid · Full-Time · 8+ years exp · Cambridge
Manager, Global Regulatory Strategy
$116k – $145k per year · Hybrid · Full-Time · 5+ years exp · Cambridge · Washington · New York
Director, Global Pharmacovigilance Operations Lead
$186k – $232k per year · Hybrid · Full-Time · 12+ years exp · Cambridge
Degree asked
Bachelor's Degree 100%
4 postings state a degree.
Benefits named in postingsshare of open roles
Equity788%
Continuous learning225%
Contract type
Full-Time 8
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family

What its postings pay, by level.

$201kMedianmarket estimate $189k
$145k – $217kTypical rangeUSD a year
$232kHighest paying roleDirector, Global Pharmacovigilance Operations Lead
Pay by levelmiddle half of stated pay, median marked · dashed: market median $189k
Senior3$170k$145k – $170k
Head+3$201k
$0$63k$125k$188k$250k
People cost

Sarepta filed a median H-1B wage of $170k in 2026.

1,362People on payrollPERM filings, 2026Source ↗
$170kMedian H-1B wage, 20267 casesSource ↗
$92k–$197kH-1B wage range7 positions
Median H-1B wage by role, 2026scale to $197k
Sr. Principal Engineer, Manufacturing Sciences & Technology · 2$151k
QC Analyst · 1$92k
Associate Director, IT Validation · 1$177k
Director, Quality Control · 1$191k
Senior Manager, CMC Regulatory Affairs · 1$144k
Source: the pay stated in the company's postings, normalised to USD a year

Named in the work visa registers of United States.

United StatesUS 8 #2,003 of 9,233 sponsors
8 ▼ 68%H-1B filings in 12 months
4Green card filings
$133kMedian offered salary
Who they sponsor
Medical scientists3
Industrial production managers2
Computer and information systems managers1
2 more occupations and the salary for eachVisa pass · 90 credits

In the register as Sarepta Therapeutics, Inc., Cambridge, MA (+1 more)

Other sponsors in the same field
See 8 open roles Alert me
US Department of Labor · latest filing Jul 7, 2026 · the register ↗

Footprint

Hiring in 11 cities in 1 country.

11Cities
1Countries
CambridgeBusiest site
Loading the map
SiteTypeOpen rolesHires most forEngineering
Cambridge United StatesHeadquarters6Biotech, Operations, Education0%
New York United StatesRegional office3Biotech, Education0%
Washington United StatesNot classified2Biotech0%
Bedford United StatesNot classified1Operations0%
Hartford United StatesNot classified1Education0%
Manchester United StatesNot classified1Education0%
Providence United StatesNot classified1Education0%
Burlington United StatesNot classified1Education0%
Source: office addresses in postings and company registers

Ranked #6 by open roles among its 11 closest peers.

#CompanyHQOpen rolesSize
1Vertex PharmaceuticalsBoston, United States2265000+
2AlnylamCambridge, United States931001-5000
3BioMarin Pharmaceutical Inc.San Rafael, United States57501-1000
4PTC TherapeuticsWarren, United States25201-500
5GenetixbiotxSomerville, United States1151-200
6SareptaCambridge, United States8501-1000
7MeiraGTxNew York, United States6201-500
8Rocket PharmaceuticalsCranbury, United States6201-500
Source: Alion's similar-companies engine (industry segments, technologies, headquarters country, size)

Financials

Revenue of $2.2B in 2025. +15.6% on the year before. Net income −$713.4M.

$2.2BRevenue2025 · +15.6%
−$713.4MNet income2025 · −403.3%
Revenue by yearas filed, with the net income
2025$2.2Bnet income −$713.4M
2024$1.9Bnet income $235.2M
2023$1.2Bnet income −$536M
2022$933Mnet income −$703.5M
2021$701.9Mnet income −$418.8M
2020$540.1Mnet income −$554.1M
2019$380.8Mnet income −$715.1M
2018$301Mnet income −$361.9M
Sources: SEC

Money

Sarepta returned $25M to shareholders in fiscal 2025 and paid $37.6M of income tax.

$37.6MIncome taxes paidFY2025
$25MDividends and buybacksFY2025
$102MCapital expenditureFY2025
From its filingssec.gov ↗
FY2023FY2024FY2025
Income taxes paid$15.1M$22.6M$37.6M
Shares bought back––$25M
Capital expenditure$76.1M$137M$102M
Stock-based compensation$182.5M$184.3M$123.4M
Taxes
Income taxes paid are in the table of its filings above.
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

Public record

Sarepta: $1.2M of EU lobbying in 2025, 13 federal court cases.

Influence
US lobbying
2025 · Tarplin, Downs & Young, LLC $330,000, Michael Best Strategies LLC $260,000 · disclosurespreview.house.gov ↗
$1.2M
Employees' political contributions, 2026 cycle
671 contributions · their own money, not the company's; names not shown · fec.gov ↗
$134k
Patents
Published US applications
65
US federal cases naming it as a party
Aug 2019 – Jul 2024 · 10 as defendant · 7 closed
Most common: 830 Patent 5, 830 Patent Infringement (Fed. Qst.) 1, 850 Securities/Commodities 1, Contract: Other 1
13
Each line links its register: the agency's page, the EU Transparency Register, the FEC, the USPTO, CourtListener.

Technologies named in job postings at Sarepta over the last 12 months, by layer, with the share of postings for each.

12Technologies in use
7Postings analysed
55/100Stack modernity
Cloud & platformsGCP
Sign in to see how your skills match this stackSign In
Full Sarepta tech stack12 technologies · by team · pay by technology · changes · similar stacks
Source: the technologies named in the company's postings and on its site

Milestones

Feb 28, 2020
Each milestone is dated by its source: registers, filings, the press

Newsroom

#300,566Web rankTranco top 1M
Oct 22026
News · BioSpace
Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented…
Sep 302026
News · Sarepta Therapeutics stock falls 1.28 percent as DMD data land
Sarepta Therapeutics stock posted Q2 revenue of USD 401.25 million and EPS of USD 0.64 on August 5, 2026. ELEVIDYS data covered older patients at the September 30 congress.
Sep 262026
News · YahooFinance
In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta ag…
Sources: the outlets named on each headline, each story once